USE OF MITOXANTRONE LIPOSOME IN COMBINATION WITH ANTI-ANGIOGENIC TARGETED DRUG FOR TREATING OVARIAN CANCER
A use of a mitoxantrone liposome in combination with an anti-angiogenic targeted drug, especially bevacizumab and sorafenib, in the treatment of ovarian cancer, especially platinum-resistant recurrent ovarian cancer. The combination of the mitoxantrone liposome and the anti-angiogenic targeted drug further improves the curative effect on ovarian cancer, disease reponse rate is improved, and the progress of the disease can be controlled, thereby providing a new choice for treating ovarian cancer..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 02. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LI CHUNLEI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-02, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 |
|---|
| Patentnummer: |
WO2023207931 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018573673 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018573673 | ||
| 003 | DE-627 | ||
| 005 | 20231229104622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231124s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018573673 | ||
| 035 | |a (EPA)WO2023207931 | ||
| 035 | |a (EPA)88517806 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LI CHUNLEI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a USE OF MITOXANTRONE LIPOSOME IN COMBINATION WITH ANTI-ANGIOGENIC TARGETED DRUG FOR TREATING OVARIAN CANCER |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-02, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 | ||
| 520 | |a A use of a mitoxantrone liposome in combination with an anti-angiogenic targeted drug, especially bevacizumab and sorafenib, in the treatment of ovarian cancer, especially platinum-resistant recurrent ovarian cancer. The combination of the mitoxantrone liposome and the anti-angiogenic targeted drug further improves the curative effect on ovarian cancer, disease reponse rate is improved, and the progress of the disease can be controlled, thereby providing a new choice for treating ovarian cancer. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIU YANPING |4 aut | |
| 700 | 0 | |a LI YANHUI |4 aut | |
| 700 | 0 | |a LUO WUXIA |4 aut | |
| 700 | 0 | |a LIANG MIN |4 aut | |
| 700 | 0 | |a LI MENGMENG |4 aut | |
| 700 | 0 | |a DU YANLING |4 aut | |
| 700 | 0 | |a WANG CAIXIA |4 aut | |
| 700 | 0 | |a LI YONGFENG |4 aut | |
| 700 | 0 | |a WANG SHIXIA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 02. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:02 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88517806/publication/WO2023207931A1?q=WO2023207931 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 02 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 02 |c 11 | ||